The NGIO IPO will be a challenge. The key is institutional support, I'm sure the sellers can't wait, so far little confidence from legit institutions (JPM, Goldman Sachs, Morgan Stanley just to name a few). No buyers no stability , I don't expect GNBT to be listed this year. As far as China.....struggle to meet target dates, imagine collecting royalties if they own the IP. Any pps calculations are meaningless unless support believes in revenue/potential/Management .......trading volume will tell the story!! Not being negative but continue to be skeptical based on 2018/19/20 results !!! All eyies on Covid .....what if vaccine is not successful. Marketing and sales have been disappointing so far.
Exciting times ahead!! Instead of adding people to the BOD add some fresh qualified/experienced Management to increase confidence/integrity!!
(0)
(3)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links